KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash from Financing Activities (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Cash from Financing Activities for 18 consecutive years, with -$802.2 million as the latest value for Q1 2026.

  • For Q1 2026, Cash from Financing Activities rose 26.35% year-over-year to -$802.2 million; the TTM value through Mar 2026 reached -$3.4 billion, down 2.75%, while the annual FY2025 figure was -$3.7 billion, 68.84% down from the prior year.
  • Cash from Financing Activities hit -$802.2 million in Q1 2026 for Regeneron Pharmaceuticals, down from -$780.1 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $64.7 million in Q1 2022 and bottomed at -$1.1 billion in Q4 2024.
  • Average Cash from Financing Activities over 5 years is -$559.8 million, with a median of -$614.2 million recorded in 2023.
  • Year-over-year, Cash from Financing Activities surged 117.66% in 2022 and then plummeted 2412.53% in 2025.
  • Regeneron Pharmaceuticals' Cash from Financing Activities stood at -$247.6 million in 2022, then crashed by 80.17% to -$446.1 million in 2023, then tumbled by 154.54% to -$1.1 billion in 2024, then skyrocketed by 31.3% to -$780.1 million in 2025, then dropped by 2.83% to -$802.2 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$802.2 million, -$780.1 million, and -$717.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.